The NM_000152.5(GAA):c.1103G>A variant in GAA is a missense variant predicted to cause substitution of glycine by aspartic acid at amino acid 368 (p.Gly368Asp). This variant has been detected in at least 4 individuals with Pompe disease and deficient GAA activity (PP4_Moderate). Of those individuals, 4 were compound heterozygous for the variant and c.-32-13T>G (ClinVar Variation ID: 4027), a variant that has been classified by the LD VCEP as pathogenic for Pompe disease, c.-32-13T>G; one of those were confirmed in trans by parental/family testing (PMID: 36246652, 33202836, internal lab data) (max 2 patients counted, 1 point for confirmed in trans and 0.5 points for unconfirmed phase, 1.5 points) (PM3)(PMID: 36246652, 33202836, internal lab data). This variant is absent in gnomAD v4.1.0 (PM2_Supporting). Expression of the variant in HEK293 cells resulted in 2.8% wild type GAA activity and evidence of abnormal GAA synthesis and processing, indicating that this variant may impact protein function (PMID: 36246652) (PS3_Supporting). The computational predictor REVEL gives a score of 0.647 which is neither above nor below the thresholds predicting a damaging (>0.7) or benign (<0.5) impact on GAA function. There is a ClinVar entry for this variant (Variation ID: 1037598, 1 star review status) with 3 other submitters including 1 classifying the variant as a VUS, 1 as Likely Pathogenic and 1 as Pathogenic. In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease based on the GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0.0): PM3, PP4_Moderate, PM2_Supporting, PS3_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on August 2, 2025).